Compound Profile: Survodutide Dragon Pharma
Survodutide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. This innovative compound represents a next-generation approach to studying incretin pathway modulation in laboratory environments. Researchers at Stroid UK Shop can investigate this compound’s unique dual-receptor mechanism that activates both GLP-1 and GIP pathways simultaneously. The Dragon Pharma formulation provides research-grade material for examining metabolic hormone interactions and glucose homeostasis mechanisms in controlled laboratory studies.
Laboratory Research Applications
Scientific studies investigate Survodutide’s dual-receptor activation in metabolic pathway research, where it demonstrates enhanced effects compared to single-receptor agonists in preclinical models. Researchers examine its mechanisms in glucose regulation, insulin sensitivity pathways, and incretin hormone signalling cascades. The compound’s dual targeting approach offers unique research opportunities for studying metabolic syndrome models and glucose homeostasis mechanisms. Laboratory investigations focus on its pharmacological profile, receptor binding characteristics, and cellular signalling pathway activation. Studies utilising compounds from our fat burner research category examine metabolic modulation mechanisms alongside traditional SARM research compounds and peptide investigations.
Technical Specifications
| Parameter | Specification |
|---|---|
| Classification | Dual GLP-1/GIP receptor agonist |
| CAS Number | Verify with supplier |
| Molecular Formula | Verify with supplier |
| Molecular Weight | Verify with supplier |
| Purity | Research grade |
| Storage | Store according to manufacturer specifications |
| Solubility | Laboratory testing required |
| Stability | Verify storage conditions |
Research Use Compliance
This product is supplied exclusively for in-vitro laboratory research purposes. Survodutide Dragon Pharma is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must comply with all applicable laboratory safety protocols and regulatory requirements when handling this research compound. All investigations must be conducted within appropriate research facilities by qualified personnel following established scientific methodologies.
